Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

786.74 +5.07 (+0.65%)
Streaming Delayed Price Updated: 12:40 PM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
News headline image
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
From Society For Science
Via GlobeNewswire
News headline image
2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years ↗
The pharmaceutical specialist has had strong momentum over the past six months, and that could continue for a while. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock? ↗
Via Stocktwits
Regeneron Pharmaceuticals (NASDAQ:REGN) Reports Q4 2025 Earnings Beat Amid Product Transition ↗
Via Chartmill
Topics Earnings
News headline image
1 No-Brainer Biotech Stock To Buy Today and Never Sell ↗
This player's pipeline should keep growth going over the long run. 
Via The Motley Fool
News headline image
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly... 
Via MarketMinute
News headline image
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data
The multi-billion dollar wet Age-Related Macular Degeneration (wet AMD) market is standing on the precipice of a transformative shift. Today, February 16, 2026, Ocular Therapeutix (NASDAQ: OCUL) is in... 
Via MarketMinute
News headline image
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only... 
Via StockStory
Topics Stocks
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Great Reversal: Tariffs Ignite Goods Inflation as Services Cool in Latest PCE Data
The latest Personal Consumption Expenditures (PCE) price index data has revealed a significant shift in the U.S. inflationary landscape, presenting a complex puzzle for the Federal Reserve. As of early... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Regeneron (REGN) Q1 2025 Earnings Call Transcript ↗
Regeneron (REGN) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Supply Chain
News headline image
Regeneron (REGN) Q2 2025 Earnings Call Transcript ↗
Regeneron (REGN) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Regeneron (REGN) Q4 2024 Earnings Call Transcript ↗
Regeneron (REGN) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Regeneron (REGN) Q3 2024 Earnings Call Transcript ↗
Regeneron (REGN) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This $24 Million Buy Amid a 45% Stock Drop Signals Conviction in a High-Margin Data Business ↗
FactSet delivers integrated financial data and analytics to institutional clients, supporting investment decisions worldwide. 
Via The Motley Fool
News headline image
Regeneron (REGN) Q4 2025 Earnings Call Transcript ↗
Regeneron (REGN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
These S&P500 stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
News headline image
Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗
Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data. 
Via Stocktwits
News headline image
Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 2.5% year on year to $3.88 billion. Its non-GAAP profit of $11.44 per share was... 
Via StockStory
News headline image
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Healthcare Stocks Poised for a Comeback in 2026 ↗
Don't wait too long to press the buy button on these comeback stories. 
Via The Motley Fool
News headline image
GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion.... 
Via MarketMinute
Topics Intellectual Property
News headline image
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗
Via MarketBeat
Topics ETFs
News headline image
3 Profitable Stocks We Think Twice About
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.